Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Case Comprehensive Cancer Center
ClinicalTrials.gov Identifier:
NCT00054236
First received: February 5, 2003
Last updated: September 11, 2012
Last verified: September 2012

February 5, 2003
September 11, 2012
May 2002
March 2011   (final data collection date for primary outcome measure)
Event-free survival by disease assessment [ Time Frame: at 28 and 100 days and then at 6, 9, 12, 18, and 24 months ] [ Designated as safety issue: No ]
Not Provided
Complete list of historical versions of study NCT00054236 on ClinicalTrials.gov Archive Site
Umbilical cord blood donor engraftment by chimerism and complete blood count (CBC) [ Time Frame: monthly for 6 months and then at 9, 12, 18, and 24 months ] [ Designated as safety issue: No ]
Not Provided
Not Provided
Not Provided
 
Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia
Pilot Study Of Multiple Umbilical Cord Blood Unit Transplantation Following Non-Myeloablative Conditioning In Patients With Hematologic Disorders Or Severe Aplastic Anemia

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Umbilical cord blood transplantation may be able to replace cells destroyed by chemotherapy.

PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy followed by umbilical cord blood transplantation in treating patients who have hematologic cancer or severe aplastic anemia.

OBJECTIVES:

  • Determine the incidence and severity of acute toxicity in patients with hematologic malignancies or severe aplastic anemia treated with a non-myeloablative conditioning regimen followed by umbilical cord blood transplantation.
  • Determine the incidence and severity of acute and chronic graft-versus-host-disease in patients treated with this regimen.
  • Determine the incidence of relapse, disease-free survival, and overall survival of patients treated with this regimen.
  • Determine the survival rate at 100 days post-transplantation in patients treated with this regimen.
  • Determine the incidence of regimen-related complications (infection, hepatic veno-occlusive disease, and interstitial pneumonitis) in patients treated with this regimen.
  • Determine the incidence of primary and secondary graft failure in patients treated with this regimen.
  • Determine the rates and kinetics of donor-derived lymphoid, myeloid, neutrophil, RBC, and platelet engraftment in patients treated with this regimen.

OUTLINE: Patients receive a non-myeloablative conditioning regimen comprising fludarabine IV over 30 minutes on days -8 to -4, cyclophosphamide IV over 2 hours on days -3 to -2, and anti-thymocyte globulin (ATG) IV over at least 4 hours on days -2 to -1. Patients unable to tolerate ATG may receive methylprednisolone IV over 1 hour on days -3 to -1.

Patients undergo multiple unit umbilical cord blood transplantation on days 0-1. Patients receive filgrastim (G-CSF) subcutaneously beginning on day 7 and continuing until blood counts recover.

Patients are followed monthly for 6 months; at 9, 12, 14, 16, 18, and 24 months; and then annually thereafter.

PROJECTED ACCRUAL: A total of 24 patients will be accrued for this study within 2 years.

Interventional
Phase 1
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Chronic Myeloproliferative Disorders
  • Leukemia
  • Lymphoma
  • Multiple Myeloma and Plasma Cell Neoplasm
  • Myelodysplastic Syndromes
  • Myelodysplastic/Myeloproliferative Diseases
  • Biological: anti-thymocyte globulin
    anti-thymocyte globulin (ATG) IV over at least 4 hours on days -2 to -1
  • Biological: filgrastim
    Patients receive filgrastim (G-CSF) subcutaneously beginning on day 7 and continuing until blood counts recover.
  • Drug: cyclophosphamide
    cyclophosphamide IV over 2 hours on days -3 to -2
  • Drug: fludarabine phosphate
    fludarabine IV over 30 minutes on days -8 to -4
  • Procedure: umbilical cord blood transplantation
    Patients undergo multiple unit umbilical cord blood transplantation on days 0-1.
  • Drug: methylprednisolone
    Patients unable to tolerate ATG may receive methylprednisolone IV over 1 hour on days -3 to -1.
Experimental: non-myeloablative conditioning regimen
Interventions:
  • Biological: anti-thymocyte globulin
  • Biological: filgrastim
  • Drug: cyclophosphamide
  • Drug: fludarabine phosphate
  • Procedure: umbilical cord blood transplantation
  • Drug: methylprednisolone
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
55
March 2011
March 2011   (final data collection date for primary outcome measure)

DISEASE CHARACTERISTICS:

  • One of the following histologically confirmed diagnoses:

    • Acquired severe aplastic anemia

      • Meets at least 2 of the following criteria:

        • Granulocyte count less than 500/mm^3
        • Platelet count less than 20,000/mm^3
        • Absolute reticulocyte count less than 20,000/mm^3 (after correction for hematocrit)
      • Unresponsive to OR recurrent disease after prior treatment with anti-thymocyte globulin and/or cyclosporine
    • Acute myeloid leukemia (AML), meeting 1 of the following criteria:

      • Failed induction therapy
      • In first complete remission (CR) with any of the following high-risk features:

        • Stem cell or biphenotype classification (M0)
        • Erythroleukemia (M6)
        • Acute megakaryocytic leukemia (M7)
        • Cytogenetic markers indicative of poor prognosis
        • t(15;17) translocation and failed first-line induction therapy OR there is molecular evidence of persistent disease
        • t(8;21) and inv(16) translocations and failed first-line induction therapy
      • In early relapse*
      • In second or subsequent remission
      • Recurrent disease after prior autologous stem cell transplantation (SCT) NOTE: *No refractory relapse
    • Acute lymphoblastic leukemia, meeting 1 of the following criteria:

      • In early relapse*
      • In second or subsequent remission
      • In first CR with the following high-risk features:

        • t(4;11) or t(9;22) translocation
        • Hyperleukocytosis (initial WBC greater than 30,000/mm^3)
        • Failed to achieve CR by day 28 of standard induction therapy
      • Recurrent disease after prior autologous SCT NOTE: *No refractory relapse
    • Chronic myelogenous leukemia

      • Chronic or accelerated phase that has failed medical management
      • Blastic phase allowed after reinduction chemotherapy induces chronic phase
    • Myelodysplastic syndromes meeting 1 of the following criteria:

      • Refractory to medical management
      • Presence of cytogenetic abnormalities predictive of transformation to acute leukemia, including the following:

= 5q- = 7q-

  • Monosomy 7 and trisomy 8
  • Evidence of evolution to AML (e.g., refractory anemia with excess blasts [RAEB], or RAEB in transformation)

    • Chronic lymphocytic leukemia

      • Refractory to treatment including fludarabine-based therapy
      • Recurrent disease after prior autologous SCT
    • Multiple myeloma

      • Recurrent disease after prior autologous SCT
      • Beyond first CR or failed induction therapy
      • Disease is sensitive to pretransplantation cytoreduction
    • Hodgkin's lymphoma

      • Beyond first CR or failed induction therapy
      • Disease is sensitive to pretransplantation cytoreduction
    • Non-Hodgkin's lymphoma (NHL)

      • Recurrent disease after prior autologous SCT
      • Beyond first CR or failed induction therapy
      • Disease is sensitive to pretransplantation cytoreduction
      • Mantle zone NHL allowed after induction therapy
    • Myeloproliferative disorders

      • Refractory to medical management
      • Allografting required unless grade 3 or greater myelofibrosis by bone marrow biopsy

        • No HLA-matched sibling donor available
        • Ineligible for a myeloablative conditioning regimen due to advanced age (over 55), extensive prior therapy, and/or other comorbidities
        • If under age 55, must meet at least 1 of the following criteria:
    • Received extensive prior therapy
    • Organ toxicity or infection precluding eligibility for allogeneic transplantation with full ablation conditioning

      • Availability of 2-5 umbilical cord blood units that are at least a 4/6 HLA match
      • No active CNS disease
      • No primary or grade 3 or 4 myelofibrosis

PATIENT CHARACTERISTICS:

Age

  • Any age

Performance status

  • Karnofsky 70-100% (for patients 16 years of age and older)
  • Lansky 50-100% (for patients under 16 years of age)

Life expectancy

  • At least 3 months

Hematopoietic

  • See Disease Characteristics

Hepatic

  • ALT/AST less than 4 times normal
  • Bilirubin less than 2.0 mg/dL (unless due to hepatic infiltration by primary malignancy)

Renal

  • Creatinine clearance greater than 40 mL/min

Cardiovascular

  • Shortening fraction or ejection fraction greater than 40% of normal value for age by echocardiogram or radionuclide scan

Pulmonary

  • FVC and FEV_1 greater than 60% of predicted
  • DLCO greater than 60% of predicted (adult patients)
  • Clearance by pulmonologist required if patient cannot perform pulmonary function tests

Other

  • Not pregnant or nursing
  • No uncontrolled active infection (viral, bacterial, or fungal)
  • HIV negative

PRIOR CONCURRENT THERAPY:

Biologic therapy

  • See Disease Characteristics
  • More than 3 months since prior autologous stem cell transplantation

Chemotherapy

  • See Disease Characteristics
  • At least 4 weeks since prior chemotherapy

Endocrine therapy

  • Not specified

Radiotherapy

  • Not specified

Surgery

  • Not specified

Other

  • Recovered from prior therapy
  • No other concurrent investigational agents that would preclude study participation or increase risk to patient

    • Investigational diagnostic procedures allowed
Both
Not Provided
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00054236
CWRU6Y01, P30CA043703, CWRU6Y01, 12-01-32J
Yes
Case Comprehensive Cancer Center
Case Comprehensive Cancer Center
National Cancer Institute (NCI)
Principal Investigator: Brenda Cooper, MD Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
Case Comprehensive Cancer Center
September 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP